MERCK MARKET SHARE ON MEDCO FORMULARIES REACHES 12%, UP FROM 10%; MERCK WILL NOT BROADEN PRODUCT LINE TO MAINTAIN MARKET SHARE, CEO GILMARTIN TELLS NYSSA

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".